ArticlePloS one2025
Evaluation of a digital health platform for preventing stroke in the Australian community: Study protocol for a randomized controlled trial - Love Your Brain.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleOne in four people will have a stroke in their lifetime. Over 80% of strokes are preventable through the management of modifiable risk factors. There is a growing demand from the community for information about how to prevent stroke. The Love Your Brain digital platform comprises an online course (Massive Online Open Course) and text messages to improve stroke knowledge and motivate behaviour change for stroke prevention.
aimsTo determine the effect of the digital platform vs a control on attendance at a medical practitioner for cardiovascular risk assessment or management, from either a general practitioner or specialist. METHODS AND
designLove Your Brain is a Phase III, prospective, single-blinded three-arm randomized controlled trial. Eligible participants are community-dwelling residents of Australia aged ≥45 years, who communicate in English language, can access internet and a smartphone, and do not have a self-reported history of stroke or major cardiovascular event. Participants are randomised to either receive the online course, text messages, or general information about stroke risk factors via email (control). Online surveys will be conducted at baseline and 12 weeks. Outcomes will be assessed based on intention-to-treat analysis. Self-reported medical visits will be validated using data linkage. Process and economic evaluations will be conducted in parallel to the trial. An independent statistician blinded to group will analyse the data. STUDY OUTCOMES AND SAMPLE SIZE: The primary outcome is a visit to a medical practitioner for cardiovascular risk assessment or management within 12-weeks of randomization. Secondary outcomes include: (1) knowledge of stroke signs and risk factors; (2) healthy or risk-modifying behaviours; (3) adherence to medications; (4) process evaluation including intervention delivery/implementation and satisfaction; (5) economic evaluation including health care resource use and cost; and (6) adverse events. Assuming 80% power (two-sided α = 0.05) and 40% prevalence in the control group, 894 participants (298 for each of three groups) will be required to detect a 30% relative increase in medical practitioner attendance for cardiovascular risk assessment or management from either a general practitioner or specialist in the intervention groups. DISCUSSION: This study will provide evidence for the efficacy of a low-cost digital health intervention (online course or text messages) to reduce the risk of stroke in the community.
trial registrationACTRN12625000124437.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.